ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026.

Total sales for the three-month period ended March 31, 2026 were $10.4 million, a 28.4% increase compared to the three-month period ended March 31, 2025. For the three-month period ended March 31:

  • Domestic sales were $9.7 million in 2026, a 35.7% increase compared to 2025
  • International sales were $0.6 million in 2026, a 30.2% decline compared to 2025
  • Tri-Shield® sales were $7.9 million in 2026, a 38.5% increase compared to 2025
  • Dual Force® & Other sales were $2.5 million in 2026, a 4.4% increase compared to 2025